Corpus Intelligence IC Memo — RIDDLE HOSPITAL 2026-04-26 09:35 UTC
IC Memo — RIDDLE HOSPITAL
Investment Committee Memorandum | PA | 186 beds | Grade C | EBITDA uplift $17.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

RIDDLE HOSPITAL

CCN 390222 | DELAWARE, PA | 186 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

RIDDLE HOSPITAL is a 186-bed suburban community hospital in DELAWARE, PA with $238.1M in net patient revenue and a -12.1% operating margin. The hospital serves a payer mix of 38.7% Medicare, 1.1% Medicaid, and 60.2% commercial.

Thesis: Undervalued. Our ML models identify $17.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -12.1% to -4.7% (+736bps).

Net Revenue HCRIS$238.1M
Current EBITDA COMPUTED$-28.8M
Operating Margin COMPUTED-12.1%
Occupancy HCRIS65.2%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS17.5%
Distress Probability ML43.2%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
99
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -12.1% places it below the state median. Among 99 size-comparable peers (93-372 beds), the median margin is -7.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (93-372), prioritizing same-state peers. 99 hospitals in the comp set.

HospitalStateBedsRevenueMargin
RIDDLE HOSPITAL (Target)PA186$238.1M-12.1%
PRESBYTERIAN MEDICAL CENTERPA328$988.5M-18.9%
UPMC MAGEE-WOMENS HOSPITALPA347$910.8M-23.9%
UPMC CHILDRENS HOSPITAL OF PGHPA317$816.7M-2.5%
GEISINGER WYOMING VALLEY MED CPA309$782.7M5.9%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
LANKENAU MEDICAL CENTERPA370$621.6M-16.4%
UPMC ALTOONAPA337$526.8M-4.8%
COMMUNITY MEDICAL CENTERPA266$474.1M3.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.0M+210bp18mo
Cost to Collect4.5%2.5%$4.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.9M+122bp9mo
Clean Claim Rate88.0%96.0%$152K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.0M
Cost to Collect
$4.8M
Denial Rate Reduction
$4.7M
A/R Days Reduction
$2.9M
Clean Claim Rate
$152K
Total EBITDA Uplift$17.5M
Current EBITDA$-28.8M
+ RCM Uplift+$17.5M
Pro Forma EBITDA$-11.3M
Current Margin-12.1%
Pro Forma Margin-4.7%
WC Released (1x)$9.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-44.3M$-14.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-44.3M$-30.6M0.00x-100.0%
Bull Case9.0x11.0x$-39.9M$12.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-39.9M$2.2M0.00x-100.0%
Bear Case11.0x10.0x$-48.7M$-88.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-48.7M$-112.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 99 hospitals with 93-372 beds
  • Same-state prioritization (n=100)
  • Comp margins: P25=-18.9% / P50=-7.6% / P75=2.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.